Journal article
Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial
The Lancet (British edition), Vol.403(10428), pp.731-740
02/2024
DOI: 10.1016/S0140-6736(24)00050-3
PMID: 38346442
Abstract
Multiple randomised trials have shown efficacy and safety of endovascular thrombectomy in patients with large ischaemic stroke. The aim of this study was to evaluate long-term (ie, at 1 year) evidence of benefit of thrombectomy for these patients.
SELECT2 was a phase 3, open-label, international, randomised controlled trial with blinded endpoint assessment, conducted at 31 hospitals in the USA, Canada, Spain, Switzerland, Australia, and New Zealand. Patients aged 18–85 years with ischaemic stroke due to proximal occlusion of the internal carotid artery or of the first segment of the middle cerebral artery, showing large ischaemic core on non-contrast CT (Alberta Stroke Program Early Computed Tomographic Score of 3–5 [range 0–10, with lower values indicating larger infarctions]) or measuring 50 mL or more on CT perfusion and MRI, were randomly assigned, within 24 h of ischaemic stroke onset, to thrombectomy plus medical care or to medical care alone. The primary outcome for this analysis was the ordinal modified Rankin Scale (range 0–6, with higher scores indicating greater disability) at 1-year follow-up in an intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT03876457) and is completed.
The trial was terminated early for efficacy at the 90-day follow-up after 352 patients had been randomly assigned (178 to thrombectomy and 174 to medical care only) between Oct 11, 2019, and Sept 9, 2022. Thrombectomy significantly improved the 1-year modified Rankin Scale score distribution versus medical care alone (Wilcoxon-Mann-Whitney probability of superiority 0·59 [95% CI 0·53–0·64]; p=0·0019; generalised odds ratio 1·43 [95% CI 1·14–1·78]). At the 1-year follow-up, 77 (45%) of 170 patients receiving thrombectomy had died, compared with 83 (52%) of 159 patients receiving medical care only (1-year mortality relative risk 0·89 [95% CI 0·71–1·11]).
In patients with ischaemic stroke due to a proximal occlusion and large core, thrombectomy plus medical care provided a significant functional outcome benefit compared with medical care alone at 1-year follow-up.
Stryker Neurovascular.
Details
- Title: Subtitle
- Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial
- Creators
- Amrou Sarraj - University Hospitals of ClevelandMichael G Abraham - University of Kansas Medical CenterAmeer E Hassan - Valley Baptist Medical CenterSpiros Blackburn - The University of Texas Health Science Center at HoustonScott E Kasner - University of PennsylvaniaSantiago Ortega-Gutierrez - University of IowaMuhammad Shazam Hussain - Cleveland ClinicMichael Chen - Rush University Medical CenterHannah Johns - The University of MelbourneLeonid Churilov - The University of MelbourneDeep K Pujara - University Hospitals of ClevelandFaris Shaker - The University of Texas Health Science Center at HoustonLaith Maali - University of Kansas Medical CenterPere Cardona Portela - Bellvitge University HospitalNabeel A Herial - Thomas Jefferson University HospitalDaniel GibsonOsman Kozak - Thomas Jefferson University HospitalJuan F Arenillas - Universidad de ValladolidBernard Yan - The University of MelbourneNatalia Pérez de la Ossa - Hospital Universitari Germans Trias i PujolSophia Sundararajan - University Hospitals of ClevelandYin C Hu - University Hospitals of ClevelandDennis J Cordato - Liverpool HospitalNathan W Manning - Ingham InstituteRicardo A Hanel - Baptist Medical Center JacksonvilleAmin N Aghaebrahim - Baptist Medical Center JacksonvilleRonald F Budzik - Riverside Methodist HospitalWilliam J Hicks - Riverside Methodist HospitalJordi Blasco - Hospital Clínic de BarcelonaTeddy Y Wu - Christchurch HospitalJenny P Tsai - Cleveland ClinicJoanna D Schaafsma - Toronto Western HospitalChirag D Gandhi - Westchester Medical CenterFawaz Al-Mufti - Westchester Medical CenterNavdeep Sangha - Kaiser PermanenteSteven Warach - The University of Texas at AustinTimothy J Kleinig - Royal Adelaide HospitalVignan Yogendrakumar - The Royal Melbourne HospitalFelix Ng - The Royal Melbourne HospitalEdgar A Samaniego - University of IowaMohammad A Abdulrazzak - Cleveland ClinicMark W Parsons - Liverpool HospitalMohammad H Rahbar - The University of Texas Health Science Center at HoustonThanh N Nguyen - Boston Medical CenterJohanna T Fifi - Icahn School of Medicine at Mount SinaiVitor Mendes Pereira - St. Michael's HospitalMaarten G Lansberg - Stanford UniversityGreg W Albers - Stanford UniversityAnthony J Furlan - University Hospitals of ClevelandPascal Jabbour - Thomas Jefferson University HospitalClark W Sitton - The University of Texas Health Science Center at HoustonCathy Sila - University Hospitals of ClevelandNicholas Bambakidis - University Hospitals of ClevelandStephen M Davis - The Royal Melbourne HospitalLawrence Wechsler - University of Pittsburgh Medical CenterMichael D Hill - University of CalgaryJames C Grotta - Memorial HermannMarc Ribo - Vall d'Hebron Hospital UniversitariBruce C V Campbell - The University of MelbourneSELECT2 Investigators
- Resource Type
- Journal article
- Publication Details
- The Lancet (British edition), Vol.403(10428), pp.731-740
- DOI
- 10.1016/S0140-6736(24)00050-3
- PMID
- 38346442
- NLM abbreviation
- Lancet
- ISSN
- 0140-6736
- eISSN
- 1474-547X
- Publisher
- Elsevier Ltd
- Grant note
- DOI: 10.13039/100008894, name: Stryker Corporation
- Language
- English
- Electronic publication date
- 02/08/2024
- Date published
- 02/2024
- Academic Unit
- Neurology; Radiology; Iowa Neuroscience Institute; Neurosurgery
- Record Identifier
- 9984559811402771
Metrics
9 Record Views